Scarica l'app Stockscreener
32.14
3.28%
-1.09
Dopo l'orario di chiusura:
31.52
-0.62
-1.93%
Panoramica
Notizia
Cronologia dei prezzi
Catena di opzioni
Financials
Forum
Previsione
Frazionamento azionario
Precedente Chiudi:
$33.23
Aprire:
$32.73
Volume 24 ore:
602.75K
Relative Volume:
0.60
Capitalizzazione di mercato:
$2.52B
Reddito:
$1.55M
Utile/perdita netta:
$-258.76M
Rapporto P/E:
-8.251
EPS:
-3.8953
Flusso di cassa netto:
$-213.66M
1 W Prestazione:
-6.05%
1M Prestazione:
+6.07%
6M Prestazione:
+23.66%
1 anno Prestazione:
+53.56%
Intervallo 1D:
$31.65
$33.04
Intervallo di 1 settimana:
$31.65
$34.96
Portata 52W:
$17.85
$35.79
Celldex Therapeutics Inc Stock (CLDX) Company Profile
Nome
Celldex Therapeutics Inc
Settore
Industria
Telefono
908-200-7500
Indirizzo
53 FRONTAGE ROAD, HAMPTON
Compare CLDX vs VRTX, REGN, ARGX, ALNY, ONC
| Azioni | Prezzo | Cap. di mercato | Reddito | Reddito netto | Flusso di cassa | EPS |
|---|---|---|---|---|---|---|
CLDX
Celldex Therapeutics Inc
|
32.14 | 2.61B | 1.55M | -258.76M | -213.66M | -3.8953 |
VRTX
Vertex Pharmaceuticals Inc
|
423.44 | 109.41B | 12.07B | 3.95B | 3.19B | 15.33 |
REGN
Regeneron Pharmaceuticals Inc
|
686.36 | 76.72B | 14.34B | 4.50B | 3.77B | 41.56 |
ARGX
Argen X Se Adr
|
776.02 | 48.20B | 4.16B | 1.29B | 734.26M | 19.58 |
ALNY
Alnylam Pharmaceuticals Inc
|
301.43 | 40.31B | 3.71B | 313.75M | 465.38M | 2.2571 |
ONC
Beone Medicines Ltd Adr
|
290.80 | 33.13B | 5.36B | 287.73M | 924.18M | 2.5229 |
Celldex Therapeutics Inc Stock (CLDX) Upgrades & Downgrades
| Data | Azione | Analista | Modifica della valutazione |
|---|---|---|---|
| 2026-04-20 | Aggiornamento | Barclays | Underweight → Overweight |
| 2026-03-23 | Aggiornamento | Wolfe Research | Peer Perform → Outperform |
| 2025-10-21 | Iniziato | Mizuho | Outperform |
| 2025-10-13 | Iniziato | Barclays | Underweight |
| 2025-04-28 | Iniziato | Canaccord Genuity | Buy |
| 2025-03-20 | Iniziato | Morgan Stanley | Overweight |
| 2025-02-13 | Iniziato | UBS | Buy |
| 2024-10-07 | Iniziato | Citigroup | Buy |
| 2024-09-30 | Iniziato | Goldman | Neutral |
| 2024-09-27 | Downgrade | Wolfe Research | Outperform → Peer Perform |
| 2024-06-18 | Iniziato | Stifel | Buy |
| 2024-06-11 | Iniziato | Wolfe Research | Outperform |
| 2023-12-20 | Iniziato | TD Cowen | Outperform |
| 2023-11-10 | Aggiornamento | Wells Fargo | Underweight → Equal Weight |
| 2023-08-22 | Iniziato | Wells Fargo | Underweight |
| 2021-09-17 | Iniziato | Jefferies | Buy |
| 2021-09-10 | Iniziato | SVB Leerink | Outperform |
| 2021-07-22 | Iniziato | Guggenheim | Buy |
| 2020-02-21 | Iniziato | Cantor Fitzgerald | Overweight |
| 2017-08-01 | Ripresa | H.C. Wainwright | Buy |
| 2016-11-07 | Iniziato | Aegis Capital | Buy |
| 2016-03-08 | Downgrade | Jefferies | Buy → Hold |
| 2016-03-07 | Downgrade | Guggenheim | Buy → Neutral |
| 2016-03-07 | Downgrade | Leerink Partners | Outperform → Mkt Perform |
| 2016-03-07 | Downgrade | Wedbush | Outperform → Neutral |
| 2016-03-01 | Iniziato | H.C. Wainwright | Buy |
| 2015-08-11 | Reiterato | Brean Capital | Buy |
| 2015-08-11 | Reiterato | Oppenheimer | Outperform |
| 2015-08-11 | Reiterato | ROTH Capital | Buy |
| 2015-06-02 | Reiterato | WBB Securities | Strong Buy |
| 2014-11-17 | Reiterato | ROTH Capital | Buy |
| 2014-03-04 | Reiterato | Oppenheimer | Outperform |
| 2013-07-08 | Reiterato | Cantor Fitzgerald | Buy |
| 2013-03-08 | Reiterato | Cantor Fitzgerald | Buy |
| 2013-02-26 | Reiterato | Oppenheimer | Outperform |
| 2013-01-10 | Reiterato | Cantor Fitzgerald | Buy |
| 2012-10-02 | Reiterato | Oppenheimer | Outperform |
| 2012-09-14 | Reiterato | Cantor Fitzgerald | Buy |
Mostra tutto
Celldex Therapeutics Inc Borsa (CLDX) Ultime notizie
Celldex earnings on deck as barzolvolimab Phase 3 nears readout - Investing.com
[ARS] Celldex Therapeutics, Inc. SEC Filing - Stock Titan
Celldex (NASDAQ: CLDX) sets 2026 virtual meeting, seeks approval for equity plan - Stock Titan
Celldex prices $300M stock at $29 per share to fuel Barzolvolimab launch - MSN
Celldex Therapeutics announces public offering of common stock - MSN
Is Celldex Therapeutics (CLDX) Still Attractive After A 70% One Year Share Price Jump - Yahoo Finance
Is Celldex (CLDX) stock a strategic buy | Q4 2025: EPS Misses ViewsCommunity Momentum Stocks - Cổng thông tin điện tử tỉnh Lào Cai
Celldex (CLDX) Operational Review | Q4 2025: Earnings UnderperformPrice Target - Cổng thông tin điện tử tỉnh Lào Cai
Assessing Celldex Therapeutics (CLDX) Valuation After Strong Recent Share Price Gains - simplywall.st
Why Celldex Stock Is Suddenly Sliding Again - TipRanks
Celldex Therapeutics Inc (CLDX) - MSN
Barclays upgrades Celldex Therapeutics (CLDX) - MSN
Celldex (CLDX) Stock VWAP Analysis (-0.49%) 2026-04-20AI Powered Stock Picks - Cổng thông tin điện tử tỉnh Tây Ninh
Celldex Therapeutics (NASDAQ:CLDX) Shares Gap Up Following Analyst Upgrade - MarketBeat
Barclays Upgrades Celldex Therapeutics to Overweight From Underweight, Adjusts Price Target to $45 From $24 - marketscreener.com
Barclays upgrades Celldex stock rating on trial enrollment progress By Investing.com - Investing.com Australia
Barclays upgrades Celldex stock rating on trial enrollment progress - Investing.com UK
Celldex (CLDX) Stock: Performance Drivers (Modest Uptick) 2026-04-18Real Trader Network - Cổng thông tin điện tử tỉnh Lào Cai
Celldex Therapeutics stock hits 52-week high at 34.55 USD By Investing.com - Investing.com India
Celldex Therapeutics (NASDAQ:CLDX) Sets New 12-Month HighHere's What Happened - MarketBeat
Celldex Therapeutics stock hits 52-week high at 34.55 USD - Investing.com
Celldex Therapeutics, Inc. (NASDAQ:CLDX) Receives Average Recommendation of "Moderate Buy" from Analysts - MarketBeat
Tudor Investment Corp ET AL Makes New $818,000 Investment in Celldex Therapeutics, Inc. $CLDX - MarketBeat
Celldex Therapeutics Spotlights Barzolvolimab as Phase III CSU Data Looms After Fast Enrollment - MarketBeat
CLDX: Barzolvolimab shows strong, durable efficacy in urticaria with pivotal phase III data due Q4 - TradingView — Track All Markets
Celldex to Present at Upcoming Investor Conference - The Manila Times
Celldex Therapeutics Raises $345 Million in Public Offering of Common Stock - Global Legal Chronicle
A Look At Celldex Therapeutics (CLDX) Valuation After Equity Raise And New Barzolvolimab Data - Sahm
Precision Trading with Celldex Therapeutics Inc. (CLDX) Risk Zones - Stock Traders Daily
What do ownership trends show for Celldex (CLDX) Stock | Price at $31.79, Up 1.39%Theta Decay - Cổng thông tin điện tử Tỉnh Sơn La
RSI Check: Why is Vistagen Therapeutics Inc stock going downBull Run & Real-Time Volume Analysis Alerts - baoquankhu1.vn
Celldex Therapeutics Closes $345M Public Stock Offering - National Today
Celldex Therapeutics Inc Azioni (CLDX) Dati Finanziari
Reddito
Reddito netto
Flusso di cassa
EPS
Celldex Therapeutics Inc Azioni (CLDX) insider trading
| Commercio interno | Relazione | Data | Transazione | Costo | #Azioni | Valore ($) | #Azioni Totale |
|---|---|---|---|---|---|---|---|
| PEPIN RONALD | SR. VP & CBO |
Dec 15 '25 |
Option Exercise |
5.47 |
19,333 |
105,714 |
20,097 |
| Jimenez Freddy A. | SVP & GENERAL COUNSEL |
Dec 04 '25 |
Sale |
29.09 |
4,166 |
121,210 |
30,796 |
1.40%
0.08%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):